Skip to content

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

Home
- Home
About BR&R
Biosimilar Approval Status
BR&R Product Profiles
- Abrilada
- Amjevita
- Avasola
- Byooviz
- Cyltezo
- Erelzi
- Eticovo
- Fulphila
- Fylnetra
- Hadlima
- Herzuma
- Hulio
- Hyrimoz
- Inflectra
- Kanjinti
- Mvasi
- Nivestym
- Nyvepria
- Ogivri
- Ontruzant
- Releuko
- Renflexis
- Retacrit
- Rezvoglar
- Riabni
- Ruxience
- Semglee
- Trazimera
- Truxima
- Udenyca
- Yusimry
- Zarxio
- Ziextenzo
- Zirabev
Contact Us
The 2023 Biosimilars Market Report

$0.00 0 items

placeholder-square

Stanton Mehr September 19, 2018

Published by Stanton Mehr

View all posts by Stanton Mehr

Published September 19, 2018

Post navigation

Previous Post placeholder-square

Leave a ReplyCancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

SM Health Comm

Search for:

Recent Posts

Sandoz to Market Samsung Bioepis’ Ustekinumab Biosimilar September 14, 2023
Outlook Therapeutics Gets FDA Rejection on Its Ophthalmologic Bevacizumab Formulation August 31, 2023
Two More Patent Settlements and Launch Dates for Ustekinumab Biosimilars August 30, 2023
Three Biosimilar Targets in CMS’s Sights August 29, 2023
What is Cordavis and Why Will It Be Important to CVS Health and Biosimilars? August 28, 2023
Sandoz Notches Approval of Tyruko, First Biosimilar to Treat Multiple Sclerosis August 25, 2023
Simplifying Biosimilar Development to Ensure Long-Term Competition August 23, 2023
Where’s Pfizer’s Adalimumab Biosimilar? August 14, 2023
Ranibizumab Biosimilar Updates: A Nascent Market but Limited Competition August 3, 2023
Projecting at Least 40% Lower 2023 Humira® Net Costs in US July 28, 2023

Recent Comments

	Drug Manufacturers’… on The Inflation Reduction Act: R…
	Drug Manufacturers’… on Thirty Years of Exclusivity fo…
	Manjiri Kulkarni on What is Cordavis and Why Will…
	MK on Where’s Pfizer’s Adalimumab Bi…
	Vinay Patel on The Adalimumab Biosimilar Grea…

Archives

Archives

Meta

Log in
Entries feed
Comments feed
WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Email Address

Top Posts & Pages

The Evolution of the Biosimilars Market
The Next-Generation Biosimilar Race: A Tale of Two Autoimmune Biologics
What Will Cost Savings on 2023 Adalimumab Biosimilars Really Be Worth?
Ziextenzo
Ustekinumab Biosimilars Update
Tocilizumab Biosimilars Approaching: Developments on Three Fronts
Sandoz to Market Samsung Bioepis' Ustekinumab Biosimilar
Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
Biosimilar Clinical Trial Costs in Terms of Expense and Time
Rezvoglar

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

Twitter
LinkedIn

Home
About BR&R
Biosimilar Approval Status
Contact Us
Terms and Conditions

Copyright

Copyright 2013-2023 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.